PCOS Renamed to PMOS: Shift to Metabolic Syndrome Focus
Key Questions
Why is PCOS being renamed to PMOS?
The proposed renaming to Polycystic Ovary/Metabolic Syndrome (PMOS) emphasizes insulin resistance as a central driver and reframes the condition as a metabolic disorder. This shift supports broader screening for diabetes and cardiovascular risks while aligning with diet-based management approaches.
How might the PMOS name change affect GLP-1 medication access?
The name change could expand eligibility for GLP-1 therapies for affected women by highlighting metabolic aspects. For Medicare patients, the Bridge Program uses BMI at therapy initiation for eligibility, requires a denied pharmacy claim first, and protects those who have lost weight.
What dietary guidance is recommended for PMOS?
Johns Hopkins provides practical Mediterranean and DASH diet guidance tailored for PMOS management. A forthcoming study will also examine effects on testosterone reduction as part of ongoing research into this metabolic focus.
The proposed renaming of Polycystic Ovary Syndrome to Polycystic Ovary/Metabolic Syndrome (PMOS) highlights insulin resistance as a central driver. This reframes the condition as a metabolic disorder, opening broader screening for diabetes and cardiovascular risk, and aligning with diet-based management. Johns Hopkins now offers practical Mediterranean/DASH dietary guidance for PMOS. New details indicate the name change could boost GLP-1 access for affected women; a Medicare Bridge Program update clarifies that BMI at therapy initiation is used for eligibility, protecting patients who have lost weight, and a denied pharmacy claim is required first. A forthcoming study will examine testosterone reduction.